(NASDAQ: LUNG) Pulmonx's forecast annual revenue growth rate of 18.27% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.21%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.76%.
Pulmonx's revenue in 2024 is $72,994,000.On average, 2 Wall Street analysts forecast LUNG's revenue for 2024 to be $3,234,284,386, with the lowest LUNG revenue forecast at $3,229,471,232, and the highest LUNG revenue forecast at $3,239,097,540. On average, 2 Wall Street analysts forecast LUNG's revenue for 2025 to be $3,912,706,240, with the lowest LUNG revenue forecast at $3,881,770,079, and the highest LUNG revenue forecast at $3,943,681,216.
In 2026, LUNG is forecast to generate $4,705,906,295 in revenue, with the lowest revenue forecast at $4,598,658,350 and the highest revenue forecast at $4,813,154,240.